Apellis Pharmaceuticals Inc
$ 40.85
0.02%
14 Apr - close price
- Market Cap 5,222,330,000 USD
- Current Price $ 40.85
- High / Low $ 40.88 / 40.78
- Stock P/E 226.94
- Book Value 2.92
- EPS 0.18
- Next Earning Report 2026-05-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.07 %
- 52 Week High 40.88
- 52 Week Low 16.10
About
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$39.93
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-10-30 | 2025-07-31 | 2025-05-05 | 2025-02-25 | 2024-11-05 | 2024-08-01 | 2024-05-07 | 2024-02-27 | 2023-11-01 | 2023-07-31 | 2023-05-04 |
| Reported EPS | -0.47 | 1.67 | -0.33 | -0.74 | -0.29 | -0.4624 | -0.28 | -0.42 | -0.73 | -1.17 | -1.02 | -1.56 |
| Estimated EPS | -0.379 | 1.55 | -0.48 | -0.54 | -0.4019 | -0.3 | -0.32 | -0.47 | -0.69 | -0.86 | -1.32 | -1.46 |
| Surprise | -0.091 | 0.12 | 0.15 | -0.2 | 0.1119 | -0.1624 | 0.04 | 0.05 | -0.04 | -0.31 | 0.3 | -0.1 |
| Surprise Percentage | -24.0106% | 7.7419% | 31.25% | -37.037% | 27.8427% | -54.1333% | 12.5% | 10.6383% | -5.7971% | -36.0465% | 22.7273% | -6.8493% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.38 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: APLS
2026-04-14 21:09:24
Apellis Pharmaceuticals (APLS) stock reached a 52-week high of $40.87, marking a 111% increase over the past year. Despite this surge, InvestingPro data suggests the stock may be overvalued with a steep P/E ratio, and analysts do not expect profitability this year. The company is set to be acquired by Biogen for $41 per share in cash, a deal that has led several analyst firms to downgrade Apellis's rating while adjusting price targets to align with the acquisition terms.
2026-04-12 14:09:37
In a major strategic move, Biogen is set to acquire Apellis Pharmaceuticals for $5.6 billion. This acquisition is primarily aimed at bolstering Biogen's immunology portfolio, indicating a significant investment in expanding its therapeutic offerings in this critical area.
2026-04-09 12:09:02
Biogen has announced its acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, aiming to enhance its immunology and rare disease portfolio. The deal includes two commercialized medicines, Empaveli and Syfovre, which generated $689 million in combined net sales in 2025 and are expected to boost Biogen's revenue growth. This acquisition also positions Biogen to accelerate the commercial readiness of felzartamab for kidney diseases, leveraging Apellis's established US sales infrastructure.
2026-04-09 11:38:58
Apellis Pharmaceuticals director Stephanie Monaghan O'Brien reported an internal share restructuring, moving 5,750 shares of Common Stock from a trust to an account held directly by her spouse. This transaction did not change her overall beneficial ownership. Following the restructuring, O'Brien now directly holds 25,666 shares and indirectly holds 5,750 shares through her spouse.
2026-04-09 10:09:02
Apellis Pharmaceuticals (APLS) has seen a significant share price surge, returning 104% in the past month. Despite this, the stock is considered 14% overvalued by some analysts, with a fair value closer to $35.71 compared to its current trading price of $40.69. The recent FDA label expansion for EMPAVELI into rare kidney diseases could drive future revenue, but watchpoints include competition and funding gaps.
2026-04-08 19:40:20
Apellis Pharmaceuticals' stock more than doubled after Biogen announced it would acquire the small biopharmaceutical firm for approximately $5.6 billion, or $41 per share. This acquisition represents a significant boost for Apellis, whose stock had previously lost nearly a third of its value this year.
